Among these new strategies, controlling co-medications, smoking status, or weight, assessing pre-treatment hormonal status combined with dexamethasone/CRH tests and T3 levels, investigating SNPs of specific genes known to be implicated in AD non-response, and the use of brain imaging or EEG to identify brain changes known to predict poor response to ADs are among the most promising. Here, CRH is linked to Alzheimer disease.